Numinus Wellness Inc. reports developments in mental health care, clinical research operations, and practitioner training tied to regulated botanical wellness-assisted therapies. The company’s updates describe Cedar Clinical Research, Numinus Practitioner Training, clinical trial site readiness, therapist education, protocols, reimbursement infrastructure, and care models for depression, anxiety, trauma, pain, and substance use.
Recurring news also covers quarterly financial results, auditor changes, exchange-listing status, cease-trade-order remediation efforts, and regulatory developments affecting botanical wellness compounds such as ibogaine, MDMA, and LSD.
Numinus Wellness has announced a strategic blueprint aimed at enhancing its presence in the U.S. and accelerating its path to profitability. The company plans to optimize costs and expand its network of wellness clinics and clinical research facilities. Key initiatives include a comprehensive membership program and a partnership with the Canadian Centre for Psychedelic Healing (Field Trip Health). This collaboration involves transitioning Numinus' Canadian therapists to Field Trip Health, closing clinics in Montreal, Toronto, and Vancouver, and leasing space for clinical trials at Field Trip Health's Vancouver clinic. The companies have also signed a 3-year training and marketing agreement to further their common interests. The plan emphasizes scalable growth, shareholder returns, and broader access to psychedelic-assisted therapies.
Numinus Wellness has announced its Cedar Clinical Research (CCR) site has been selected for Cybin's Phase 3 clinical trial of CYB003 for Major Depressive Disorder (MDD). The trial, set to begin enrollment mid-2024, follows promising Phase 2 results where 75% of participants achieved remission from depression symptoms. The U.S. FDA has granted breakthrough therapy designation for CYB003. The Murray, Utah location is among the 15 U.S. sites chosen for the study. Dr. Paul Thielking will lead the trial as Principal Investigator. This partnership aims to advance psychedelic-assisted therapy and address unmet needs in mental health care.
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF), a mental health care company focused on psychedelic-assisted therapies, has received Health Canada approval for a new study. The trial will explore the feasibility of a group model for MDMA-assisted psychotherapy, aiming to determine the optimal number of therapists needed for group sessions. The study will involve trainee practitioners who will gain core competencies by observing seasoned therapists and experiencing MDMA in a therapeutic setting. This research aims to enhance the understanding of administering MDMA for severe mental disorders like PTSD.
Numinus Wellness Inc. announces a strategic plan to focus on U.S. operations for higher growth and profitability. The company is enhancing its wellness clinics and clinical research facilities, launching a membership program for healthcare professionals in psychedelic-assisted therapies, and collaborating with Field Trip Health. Numinus also entered into an agreement with Field Trip Health to transition Canadian clinic operations, aiming to optimize therapy and training expertise while maximizing shareholder returns.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.